logo for INmune Bio

INmune Bio

Business Services · Florida, United States · <25 Employees

View Company Info for Free

About

Headquarters

225 NE Mizner Blvd Ste 640, Boca Raton, Florida...

Phone Number

(858) 964-3720

Revenue

<$5 Million

Stock Symbol

INMB

Industry

Drug Manufacturing & Research Pharmaceuticals Healthcare

Most Recent Scoops

May 24 2024
Earnings
May 24 2024
Earnings
INmune Bio has recently released 2024 Q1 report with the following insight: Pain points include unpredictability around regulatory approvals, even with positive data; challenges enrolling Alzheimer’s trials during a pandemic; and manufacturing scale-up for cell therapy products like INKmune. The need to close enrollment in the Alzheimer’s open label extension due to supply and financial constraints is also a pain point.
See all scoops

Who is INmune Bio

INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate im mune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.Read more

INmune Bio's Social MediaPopular SearchesInmune Bio IncINmune BioInmunebioINmuneBio IncSIC Code 87,873NAICS Code 32,325Ticker NASDAQ: INMBShow more

INmune Bio Org Chart

PhoneEmail
Cory Ellspermann

Controller & Vice President, Finance

PhoneEmail

PhoneEmail

PhoneEmail

Is INmune Bio your ideal costumer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Similar Companies to INmune Bio

See more similar companies
Illustration of an envelope

INmune Bio Tech Stack

A closer look at the technologies used by INmune Bio

Top Companies in United States

Top 10 companies in United States by revenue

Top 10 companies in United States by number of employees

Top 10 companies in United States by total funding amount

See top companies

Most Recent Scoops

May 24 2024
Earnings
May 24 2024
Earnings
May 24 2024
Earnings
INmune Bio has recently released 2024 Q1 report with the following insight: Pain points include unpredictability around regulatory approvals, even with positive data; challenges enrolling Alzheimer’s trials during a pandemic; and manufacturing scale-up for cell therapy products like INKmune. The need to close enrollment in the Alzheimer’s open label extension due to supply and financial constraints is also a pain point.
Financial Planning
May 24 2024
Earnings
INmune Bio has recently released 2024 Q1 report with the following insight: Key risks include the ability to fully enroll the Phase 2 Alzheimer’s trial by mid-2024 as expected and generate positive efficacy data; completing enrollment and seeing positive Phase 1/2 data for the INKmune prostate cancer program on the timeline anticipated; having sufficient funding to advance the pipeline with only $26M cash currently, although additional funding was recently secured; and obtaining regulatory approvals which are unpredictable.
May 24 2024
Earnings
INmune Bio has recently released 2024 Q1 report with the following insight: INmune Bio sees opportunities for growth in expanding XPro into additional CNS disorders beyond Alzheimer’s disease, such as treatment-resistant depression. The company plans to initiate a Phase 2 trial of XPro in treatment-resistant depression patients in the second half of 2024. INmune Bio also sees opportunities in expanding the INKmune platform into additional solid tumor cancers beyond prostate cancer, with preclinical data supporting potential in ovarian and renal cell cancers which could be future clinical targets pending resources.
See more scoops

INmune Bio News & Media

Read more news

Frequently Asked Questions regarding INmune Bio

Where is INmune Bio located?
INmune Bio's headquarters are located at 225 NE Mizner Blvd Ste 640, Boca Raton, Florida, 33432, United States
What is INmune Bio's phone number?
INmune Bio's phone number is (858) 964-3720
What is INmune Bio's stock symbol?
INmune Bio's stock symbol is INMB
What is INmune Bio's official website?
INmune Bio's official website is www.inmunebio.com
What is INmune Bio's Revenue?
INmune Bio's revenue is <$5 Million
What is INmune Bio's SIC code?
INmune Bio's SIC: 87,873
What is INmune Bio's NAICS code?
INmune Bio's NAICS: 32,325
How many employees does INmune Bio have?
INmune Bio has <25 employees
What industry does INmune Bio belong to?
INmune Bio is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare
What is INmune Bio competition?
INmune Bio top competitors include: Nantkwest, Checkmate Pharmaceuticals, EpicentRx, PDS Biotechnology
What technology does INmune Bio use?
Some of the popular technologies that INmune Bio uses are: goo.gl, Google Website Translator, Google Universal Analytics, Cloudflare CDN
How do I contact INmune Bio?
INmune Bio contact info: Phone number: (858) 964-3720 Website: www.inmunebio.com
What does INmune Bio do?

INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TN... F, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.Read More

What are INmune Bio social media links?
INmune Bio Linkedin page INmune Bio Twitter page INmune Bio Facebook page
Is INmune Bio a public company?
Yes, INmune Bio is a public company and is traded under the symbol INMB
See more information about INmune Bio

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.